SENSEI BIOTHERAPEUTICS INC (SNSE) Stock Price & Overview
NASDAQ:SNSE • US81728A2078
Current stock price
The current stock price of SNSE is 26.88 USD. Today SNSE is down by -8.85%. In the past month the price decreased by -11.05%. In the past year, price increased by 164.41%.
SNSE Key Statistics
- Market Cap
- 33.869M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -19.13
- Dividend Yield
- N/A
SNSE Stock Performance
SNSE Stock Chart
SNSE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SNSE. When comparing the yearly performance of all stocks, SNSE is one of the better performing stocks in the market, outperforming 98.69% of all stocks.
SNSE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNSE. SNSE has a great financial health rating, but its profitability evaluates not so good.
SNSE Earnings
SNSE Forecast & Estimates
6 analysts have analysed SNSE and the average price target is 33.15 USD. This implies a price increase of 23.33% is expected in the next year compared to the current price of 26.88.
SNSE Groups
Sector & Classification
SNSE Financial Highlights
Over the last trailing twelve months SNSE reported a non-GAAP Earnings per Share(EPS) of -19.13. The EPS increased by 19.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.5% | ||
| ROE | -104.92% | ||
| Debt/Equity | 0 |
SNSE Ownership
SNSE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.23 | 366.329B | ||
| AMGN | AMGEN INC | 15.47 | 190.793B | ||
| GILD | GILEAD SCIENCES INC | 15.49 | 171.639B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.41 | 115.576B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.19 | 79.234B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.98 | 43.592B | ||
| INSM | INSMED INC | N/A | 31.968B | ||
| NTRA | NATERA INC | N/A | 27.973B | ||
| BIIB | BIOGEN INC | 11.88 | 27.764B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.83 | 23.738B | ||
| MRNA | MODERNA INC | N/A | 21.145B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.686B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SNSE
Company Profile
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 14 full-time employees. The company went IPO on 2021-02-04. The firm's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The firm is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Company Info
IPO: 2021-02-04
SENSEI BIOTHERAPEUTICS INC
1405 Research Blvd, Suite 125
Rockville MARYLAND 20850 US
CEO: John Celebi
Employees: 14
Phone: 18008998648
SENSEI BIOTHERAPEUTICS INC / SNSE FAQ
Can you describe the business of SENSEI BIOTHERAPEUTICS INC?
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 14 full-time employees. The company went IPO on 2021-02-04. The firm's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The firm is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.
What is the stock price of SENSEI BIOTHERAPEUTICS INC today?
The current stock price of SNSE is 26.88 USD. The price decreased by -8.85% in the last trading session.
Does SENSEI BIOTHERAPEUTICS INC pay dividends?
SNSE does not pay a dividend.
What is the ChartMill rating of SENSEI BIOTHERAPEUTICS INC stock?
SNSE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of SNSE stock?
SENSEI BIOTHERAPEUTICS INC (SNSE) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for SNSE stock?
SENSEI BIOTHERAPEUTICS INC (SNSE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-19.13).
Can you provide the upcoming earnings date for SENSEI BIOTHERAPEUTICS INC?
SENSEI BIOTHERAPEUTICS INC (SNSE) will report earnings on 2026-03-26, after the market close.